Osteopontin-Derived Peptides
Osteopontin-derived peptides, including the thrombin-cleaved SVVYGLR fragment and RGD-containing sequences, are bioactive fragments of the extracellular matrix protein osteopontin (OPN). These peptides mediate angiogenesis, integrin-dependent cell adhesion, immune cell recruitment, and bone remodeling through distinct receptor interactions.
Osteopontin (OPN) is a multifunctional phosphorylated glycoprotein expressed in bone, immune cells, and various epithelial tissues. When cleaved by thrombin at its conserved cleavage site (Arg168-Ser169 in human OPN), it generates bioactive fragments with distinct receptor-binding properties.
Overview
Osteopontin was first identified in 1986 as a bone matrix protein, but has since been recognized as a pleiotropic cytokine involved in immune regulation, biomineralization, and tissue remodeling. The full-length protein contains multiple functional domains including the RGD integrin-binding motif, thrombin cleavage site, heparin-binding domain, and calcium-binding sites. Thrombin cleavage is a physiologically important post-translational event that modulates OPN activity at sites of injury, inflammation, and coagulation.
The SVVYGLR peptide, exposed only after thrombin cleavage, has attracted particular research interest for its potent angiogenic activity and its role as a minimal bioactive fragment for biomaterial functionalization. Unlike the full RGD-dependent adhesion pathway, SVVYGLR engages distinct integrin receptors and downstream signaling cascades, making these two OPN-derived motifs complementary rather than redundant.
Mechanism of Action
Osteopontin-derived peptides exert their effects through distinct integrin-mediated pathways:
- SVVYGLR-integrin signaling: The SVVYGLR heptapeptide binds alpha9beta1 and alpha4beta1 integrins, triggering endothelial cell migration, tubule formation, and angiogenesis through FAK/ERK signaling cascades. This interaction is independent of the RGD motif and represents a distinct pro-angiogenic mechanism
- RGD-integrin adhesion: The RGD motif binds alphavbeta3, alphavbeta5, and alphavbeta1 integrins, mediating cell adhesion, osteoclast attachment to bone surfaces, and tumor cell migration. This interaction activates PI3K/Akt survival signaling and NF-kappaB-dependent gene expression
- Immune cell chemotaxis: OPN fragments recruit macrophages, T cells, and dendritic cells through CD44 receptor engagement (via the C-terminal fragment) and integrin-mediated pathways, modulating both innate and adaptive immune responses
- Osteoclast regulation: Full-length and cleaved OPN regulate osteoclast adhesion and resorption on bone surfaces through alphavbeta3 integrin engagement, linking these peptide fragments to bone remodeling homeostasis
Reconstitution Calculator
Reconstitution Calculator
Calculate your peptide dosing
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Angiogenesis and Endothelial Cell Migration
The SVVYGLR peptide is one of the most potent short peptide promoters of angiogenesis. Senger et al. (2005) demonstrated that this thrombin-exposed motif is necessary and sufficient for OPN-mediated endothelial cell migration and tubule formation. The peptide promotes angiogenesis at concentrations comparable to VEGF in some in vitro assays, making it an attractive candidate for biomaterial functionalization.
Yukari et al. (2012) showed that SVVYGLR-containing peptides promote angiogenesis in vivo when incorporated into collagen or hydroxyapatite scaffolds, with significantly enhanced vascular density compared to RGD-functionalized or unmodified scaffolds.
Tumor Microenvironment
OPN is highly expressed in many solid tumors and contributes to the metastatic microenvironment. The RGD domain promotes tumor cell adhesion and invasion through alphavbeta3 integrin activation, while SVVYGLR-mediated angiogenesis supports tumor vascularization. Rangaswami et al. (2006) showed that thrombin cleavage of OPN in the tumor microenvironment generates fragments that enhance both tumor cell migration and immune evasion.
Wound Healing Applications
SVVYGLR-functionalized biomaterials have been explored for wound healing applications. The peptide's ability to simultaneously promote angiogenesis and recruit reparative immune cells makes it suitable for incorporation into wound dressings, hydrogels, and tissue engineering scaffolds. Studies have demonstrated enhanced dermal wound closure and vascularization when SVVYGLR peptides are delivered from collagen-based biomaterials.
Immune Cell Recruitment
OPN and its fragments are potent chemoattractants for macrophages, dendritic cells, and T lymphocytes. The N-terminal thrombin fragment containing SVVYGLR recruits inflammatory monocytes through alpha4beta1 and alpha9beta1 integrin engagement, while the C-terminal fragment signals through CD44v6. Ashkar et al. (2000) demonstrated that OPN-deficient mice show impaired macrophage recruitment and Th1 immune responses, establishing OPN as a critical immune mediator.
Bone Remodeling
Osteopontin is one of the most abundant non-collagenous proteins in bone matrix, where it plays dual roles in mineralization regulation and osteoclast function. OPN-derived RGD peptides mediate osteoclast attachment to bone surfaces, a prerequisite for bone resorption. Chellaiah et al. (2003) demonstrated that OPN-integrin interactions regulate osteoclast motility and podosome dynamics, essential for efficient bone resorption.
The balance between SVVYGLR-driven angiogenesis (supporting osteoblast function through vascular supply) and RGD-mediated osteoclast adhesion positions OPN-derived peptides as central regulators of bone remodeling coupling.
Safety Profile
Osteopontin-derived peptides are endogenous fragments of a naturally occurring extracellular matrix protein. As research-stage compounds, formal toxicology studies are limited. The primary safety considerations relate to the dual nature of their biological activities:
- Angiogenesis: SVVYGLR's potent pro-angiogenic activity raises theoretical concerns in the context of existing tumors or proliferative retinopathy
- Immune modulation: OPN fragments can promote either pro-inflammatory or anti-inflammatory responses depending on cleavage state and receptor context
- Tumor biology: Given OPN's established role in tumor progression and metastasis, therapeutic use of OPN-derived peptides requires careful consideration of oncologic risk
No clinical trials using isolated SVVYGLR or RGD-derived OPN peptides have been reported. Current applications are limited to preclinical biomaterial studies and in vitro research.
Pharmacokinetic Profile
Quick Start
- Route
- Experimental: scaffold-loaded, injectable hydrogel
Interactions
Peptide Interactions
Osteopontin (OPN) is a key regulator of bone remodeling, promoting both osteoclast attachment and osteoblast function depending on context. Bisphosphonates alter bone turnover dynamics. OPN levels are often used as biomarkers of bone metabolism; bisphosphonate therapy significantly reduces circulating OPN. The interaction of exogenous OPN peptides with bisphosphonate therapy is not fully characterized. (Reinholt et al., 1990, Proc Natl Acad Sci)
Quality Indicators
What to look for
- Naturally occurring compound
- Extensive peer-reviewed research base
Red flags
- No clinical trials conducted
Frequently Asked Questions
References (8)
- [8]Hamada Y et al. Angiogenic activity of osteopontin-derived peptide SVVYGLR. Biochem Biophys Res Commun (2003)
- [2]Smith LL et al. Osteopontin N-terminal domain contains a cryptic adhesive sequence recognized by alpha9beta1 integrin. J Biol Chem (1996)
- [3]Senger DR et al. Angiogenesis promoted by vascular endothelial growth factor: regulation through alpha1beta1 and alpha2beta1 integrins. Proc Natl Acad Sci USA (1997)
- [5]Chellaiah MA et al. Osteopontin deficiency produces osteoclast dysfunction due to reduced CD44 surface expression. Mol Biol Cell (2003)
- [6]Rangaswami H et al. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol (2006)
- [7]Denhardt DT et al. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest (2001)
- [1]Yokosaki Y et al. The integrin alpha(9)beta(1) binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin. J Biol Chem (1999)
- [4]Ashkar S et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science (2000)
Orforglipron
Orforglipron (LY3502970) is an oral non-peptide small molecule GLP-1 receptor agonist developed by Eli Lilly. It is the first oral non-peptide GLP-1 agonist to reach Phase 3 clinical trials, offering once-daily dosing without fasting requirements and demonstrating significant weight loss and glycemic improvement.
Ovagen
Ovagen (Thr-Glu-Asp-Phe) is a synthetic tetrapeptide bioregulator targeting hepatic and gastrointestinal tissue, researched for hepatoprotective effects, liver aging, and gene expression modulation in hepatocytes. Developed at the St. Petersburg Institute of Bioregulation and Gerontology.